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Abstract 
In clinical trials, the need to obtain patient’s consent by way of informed consent has been 
mandatorily imposed as a way to protect the patient as subject. Unfortunately,  many studies 
have shown that the doctor-investigators had failed to disclose full information to patients. 
Hence, the aim of this paper is to examine the factors for non-disclosure of information by 
doctor-investigator and provide potential solutions to the problem. This study employed a 
mixed-method data collection that is library research and interview. A qualitative methodology 
and analysis were used in an open-ended, face-to-face interviews with 12 patients recruited to 
participate in a trial to investigate drug for chemotherapy and schizophrenia. This study reveals 
that doctor-investigators fail to disclose information due to the absence of monitoring by the 
ethics committees and that the Good Clinical Practice Training Curriculum (GCPTC) is too basic 
and almost introductory and the attitude of the patient that put high hopes on doctor-
investigators. Hence, random monitoring by the ethics committees and monitoring using video 
tape during the informed consent process are recommended. In addition, GCPTC needs to be 
improvised and further enhanced by inserting topic on the differences of objective between 
medical treatment and clinical trials and topic on infamous conduct according to Code of 
Profesional Conduct 1987 (CPC). In addition, a framework model in respect of information 
disclosure is also proposed by incorporating several new clauses in the CPC equivalent to the 
requirements of internationally recognized rights of patient as subject. 
 
Keywords: Informed Consent, Clinical Trials, Doctor-investigators, Patients, Information    
                         Disclosure. 
 
1. Introduction 
Clinical trials or medical research using human as subject has proven to improve the welfare of 
mankind by solving medical problems by finding better ways to prevent, diagnose or treat 
diseases and disorders, test new medicines or devices or to discover about health problems. In 
order to safeguard the subject, the need to obtain patient’s consent by way of informed consent 
has been made compulsory to justify the patient’s recruitment. This is because the risks to the 
patient as subjects are inevitable. Therefore, the information about risks is important to disclose 
so that the patient can decide voluntarily whether to accept or reject the doctor’s invitation to 
participate in clinical trials (Yuhanif et al., 2015). 
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Informed consent in clinical trials has been declinated in general as a negotiation or 
communication process between the doctor-investigator and the patient for the purpose of 
obtaining the patient’s consent to participate in the trial. The doctor-investigator must disclose 
full information about the trial during this process, among them are the objective of the trial, 
purpose of the trial, procedures of the trial, alternative methods available, probable benefits and 
risks, the possibility of being randomised and that the patient’s involvement is voluntary 
whereby the patient can withdraw from the study whenever he/she wanted without jeopardizing 
his/her current or future treatment (Levine, 1986).  
Unfortunately, many studies have shown that doctors failed to disclose full information to 
patients which includes the risks (Liao, Sheehan & Clarke, 2009; Rathor et al., 2011). A study 
involved 17 patients recruited to participate in a study to evaluate the safety and effectivenes of 
the investigational stent after been diagnosed with coronary artery disease and also in a study to 
investigate drug for antidepressant by Yuhanif, Anisah and Zaki Morad (2014) also has revealed 
that doctor-investigators fail to disclose full information to patient-subjects. Instead, doctor-
investigators only disclosed information which they thought were necessary for the patient-
subjects to know. The study also showed that there were doctor-investigators who did not 
disclose information at all to the patient-subjects. Hence, the aim of this paper is to examine the 
reasons for non-disclosure of information by doctor-investigator during the process of obtaining 
informed consent in clinical trials. This paper also aim to propose solutions to the problem. A 
qualitative methodology and analysis were used in an open-ended, face-to-face interviews with 
12 patients recruited to participate in a trial to investigate drug for chemotherapy and 
schizophrenia. 
2. Reasons for Non-Disclosure 
 
There are two reasons for non-disclosure of information by doctor-investigators which are 
process and attitude. As to process, there are two reasons which have led the doctor-investigator 
not to disclose full information about the trials to the patient since there are the absence of 
monitoring by ethics committees and the Good Clinical Practice Training Curriculum by the 
Ministry of Health is too basic and almost introductory. Regarding the attitude of a patient, 
he/she has high expectations on the 'doctor' which indirectly has enabled doctor-investigators to 
practice the principle of therapeutic privilege, an act of paternalism that has been brought into 
the process of consent taking in clinical trials causing doctor-investigators to restrain from 
disclosing full information to patients. 
 
Monitoring is generally not done by the ethics committee. However, at the Ministry of Health 
for example, monitoring cannot be done on the ground that since all the members of the ethics 
committee are full-time staff who are bound by their official duties as doctors (personal 
communication with Dr. Zaki Morad Mohamad Zaher, former Chairman of  Malaysian Research 
Ethics Committee, October 10, 2015). Meanwhile, at the National Heart Institute as another 
example, the monitoring is only done based on the complaints made to the ethics committees 
either by the patients themselves or other individuals who were involved in the trials (personal 
communication with Dr. Suhaini Kadiman, Chairman of National Heart Institute Ethics 
Committees, June 24, 2015). 
 
Conversely, the current practise is that the ethics committee will give approval to the doctor-
investigator after conducting the reviewing process of the proposed research protocol based on 
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the documentation i.e. Patient Information Sheet & Informed Consent Form.1 Interview session 
with doctor-investigator will only be carried out if the ethics committee feels that there is a need 
for further explanation or doubt arises. Unfortunately, nothing has been done by the ethics 
committee to ensure that the implementation is based on procedures. For example, by conduct 
monitoring during the informed consent process to make sure the doctor-investigator disclose 
full information to patient as what is provided in the Patient Information Sheet & Informed 
Consent Form. Indeed, the problem of the absence of monitoring by the ethics committee is not 
an exception in other countries that conduct clinical trials. As Fleischman put it, local IRBS have 
been criticised for excessive focus on the informed consent form, rather than the process, and 
for neglecting other equally important aspects of ethical review such as conflict of interest and 
confidentiality (Fleischman, 2005). 
 
It is important to note that the Good Clinical Practice Training Curriculum is so basic and 
almost introductory. Important topics such as the difference objective between medical 
treatment and clinical trials and topic related to infamous conduct under the Code of 
Professional Conduct 1987 are not included. To elaborate, in medical treatment, doctors could 
decide not to disclose information for the best interest of the patients. Known as the doctor’s  
‘therapeutic privilege’, this was accepted by Lord Scarman in the leading case of Siddaway v. 
Board of Governors of the Bethlem Royal Hospital and the Maudsley Hospital ([1985] A.C. 
871; [1985] 1 AII E.R. 643; B.M.L.R. 15 (H.L.)). This principle exempts doctors from disclosing 
risky information at his/her discretion, especially if by doing so will cause harm or trauma to 
patients. However, this principle is not recognised in clinical trials as Kennedy ad Grubb (2000) 
have argued, ”Lord Scarman’s recourse [in the case of Siddaway] to the ‘therapeutic privilege’ as 
justifying non-disclosure of information does not apply to information relating to the fact that 
the patient is in clinical trial and what that entails.” In clinical trials, patient-subjects 
‘voluntarily’ accept the risks inherent in a trial for the benefit of  future patients and not 
themselves. This is because clinical trials focus on creating an overall knowledge for the benefit 
of future patients, a process requiring the doctor-investigator to conduct trial according to a 
protocol and not according to what is individually best for the patient-subject (Morreim, 2005). 
Previous experience too has demonstrated that patient-subjects cannot rely on the beneficence 
of doctors in the clinical trials arena (Lenrow, 2006).  Therefore, the need to obtain patient-
subjects’ consent by way of informed consent has been made compulsory to justify the patient-
subjects’ recruitment in clinical trials. In fact, a doctor-investigator is put on a high standard of 
duty to disclose information (Moore v. Regents of the University of California, 1990). 
Unfortunately, the difference objective between medical treatment and clinical trials is not 
included as one of the topic in the Good Clinical Practice Training Curriculum. 
 
This study showed that patients in general placed high hopes on ‘doctor’. This attitude has 
indirectly encouraged the doctor-investigator not to disclose information by adopting the 
principle of therapeutic privilege, a practice seen in normal doctor-patient relationship. In other 
words, in medical treatment the doctors are excluded from disclosing information for the best 
interest of the patients by adopting this principle. This act of paternalism has been brought into 
the process of consent taking in clinical trials. The special relationship that exist between 
                                                          
1 Since every research protocol for clinical trials must be reviewed and approved by the ethics committee, doctor-
investigators must show how a trial participation’s consent will be obtained. Legally, the Patient Information Sheet 
(PIS) & Informed Consent Form are very important legal documents in relation to patient as subject. Failure to 
adhere to the legal requirements of obtaining a valid and proper informed consent in clinical trials may potentiallly 
lead to a civil negligence action by patient, as it constitutes a breach of the medical duty of care. The patient may even 
claim legal remedies by alleging that there had been fraudulent misrepresentation, and a criminal offence under Penal 
Code and/or civil negligence actions in that there was a failure to obtain informed consent resulting in injury. 
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‘doctor’ and patient has led patients to believe and feel confident that the ‘doctor’ will act in their 
best interest. Hence, in general the patient does not ask the ‘doctor’ for information. In addition, 
the fact that ‘doctors’ have greater medical knowledge has also caused patient-subjects to rely on 
them to make decision (Yuhanif, Anisah & Rejab, 2015). However, the paternalism of doctor 
needs to be balanced with the autonomy of the patient since the the patient's right to be 
informed and give consent have been recognized as patients' rights and it is already enshrined in 
the Patients Charter 1995 (Anisah, 2008). Therefore, if the doctor does not disclose full 
information as prescribed in the Malaysian Guidelines for Good Clinical Practice2  it directly 
imputes the doctor-investigator has neglected or ignored his/her professional responsibilities 
which have been set by the Code of Professional Conduct 1987.3 As a result, a doctor-investigator 
may be disciplined because of abusing privileges and professional skills that is known as 
infamous conduct.  
3. Recommendations for Non-Disclosure of Information 
By taking into account the importance of monitoring carried out during the process of informed 
consent with the view to safeguard the patient as well as to put the seal on recognition of 
patients' rights globally, the authors suggested that it should be done in two methods, namely : - 
3. 1 Recommendations Relating to the Standard Operating Procedures 
(a) Monitoring through the usage of video footage during the process of conducting 
informed consent. 
 
Two copies must be submitted to the body which inter alia is a copy to the ethics 
committee  and another to the archives to be stored for seven years. Should, for example 
complaints arise regarding any doctor-investigator who failed to disclose information 
about the study to the patient, then the video recording will be analyzed to varify the 
authenticity of that allegations or complains. This is because the procedurially procured 
patient signatures on Patient Information Sheet and Consent Form is sine qua non and 
as a sign of approval for patients to participate in clinical trials exemplified the facts that 
there were aspects of compliance within procedural rigidity that must be observed and 
steadfastly cannot be foresaken at whatever instances, as the case may be. However, 
there are ways that doctor-investigators elude the same way as they could indiscreetly 
sheild their wayward actions hidding behind the guise of documentation stating 
otherwise the full and frank disclosure had been administered. Thus, to prove that the 
doctor-investigator does not submit complete information on compliance to Malaysian 
Guidelines for Good Clinical Practice is by way of analyzing video recordings during the 
process of informed consent. 
 
(b) Random monitoring by ethics committee. 
This monitoring can be done by selecting a few patient-subjects involved in a study to be 
interviewed to ensure that every one of them had run through the rigiour of the acid rain 
test of the interview processes and that informed consent had been procured. If it is 
found that the doctor-investigator does not conduct the process of informed consent, 
                                                          
2 Malaysian Guidelines for Good Clinical Practice is the only existing guidelines related to clinical trials in Malaysia at 
https://www.mrc.ac.uk/documents/pdf/malaysian-guidelines-for-good-clinical-practice/ 
3 Code of Professional Conduct 1987 is a code governing the practice of medical practitioners including doctor-
investigators who are registered under the Medical Act 1971 so as not to act contrary to the norms of professional 
conduct of a medical practitioner. Any misconduct from any profession according to the Code can be subject to 
disciplinary action by the Malaysian Medical Council. 
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then action may be taken against him/her by terminating the study and subsequently call 
the doctor- investigator involved for questioning. If it is proven that the doctor-
investigators have neglected the process of informed consent, then sterned action will be 
taken against them. The insignificant numbers of experts who form the composition of 
the ethics committees too need to be addressed. The present number of vis-a-vis the 
national trashhold numbers of doctor-investigators warrant a review of the said 
composition in the ethics committee. As such, the authors suggested to form a large 
secretariat of 30 to 50 experts to assist the independent body monitoring the ethical 
duties. However, members of the secretariat should be among those who have regular 
duties related to ethics independent body. For example, in the Ministry of Health, the 
secretariat of the Institute of Health Management is responsible for the Malaysian 
Research Ethics Committee (MREC) and the duties associated with clinical trials. Thus, 
the authors have suggested that the secretariat includes expertise to assist MREC 
monitoring duties. MREC members consist of doctors who are unable to perform the 
task of monitoring because they are tied to their official duties. Members of the existing 
secretariat features are not authorized to perform monitoring and they per se do the 
administrative work related to clinical trials only. Thus, the authors have also suggested 
that the secretariat should authorize representative from MREC to perform the task of 
monitoring and MREC should only focus on the process of reviewing the protocol. 
Hence, the members should be enlarged so that the monitoring process can be 
implemented effectively. The authors believe that this proposal is not dauntingly 
impossible to be implemented since the structure and training is already emplaced and 
intact. 
3. 2 Recommendations to strengthen Good Clinical Practice Training 
Curriculum 
For a doctor to be qualified as a doctor-investigator, he/she must run the guntlet and be certified 
to have passed the certificate for Good Clinical Practice Training Curriculum. In this training, 
they are given exposure to ethics and the law on the procedure for good clinical trials practices 
and governance. However, the Good Clinical Practice Training Curriculum should be further 
enhanced to make it relevant and in accordance with the requirements of the current and good 
practice. Here are some suggestions for improvement to the Good Clinical Practice Training 
Curriculum: - 
 
(a) To include topics related to the difference objective between standard medical treatment 
and clinical trials  
In medical treatment, doctors could decide not to disclose information for the best interest of 
the patients by adopting the principle of therapeutic privilege. This principle exempts doctors 
from disclosing risky information at his/her discretion especially if by doing so will cause harm 
or trauma to patients (Yuhanif et al., 2015). However, this principle is not recognised in clinical 
trials. The objective of clinical trials being conducted is to offer benefits to future patients at the 
expense of the patients themselves. This is because clinical trials focus on creating an overall 
knowledge for the benefits of future patients, a process requiring the doctor-investigator to 
conduct trial according to a protocol and not according to what is individually best for the 
patient-subjects (Morrein, 2005). Moreover, the risks inherent in a trial cannot be discounted 
and averted by the patient. It may be a small one, but it is always there (McCance, 1951). 
Conversely, the need to obtain patient’s consent by way of informed consent has been made 
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obligatory to safeguard the patients. Article 1 of Nuremberg Code4 in 1974 provides that: “The 
voluntary consent of the human subject is absolutely essentials” (US Government Printing 
Office: The Nuremberg Code, 1949). The doctor-investigator must fully disclose information 
about the trial to the patient. 
 
(b) To include topics related to infamous conduct in accordance to the Code of Professional 
Practice 1987 
 
Generally, patients place high hopes on the doctor. However, the paternalism of doctors needs 
to be balanced with the autonomy of the patient because the concept of patient’s rights has been 
recognized internationally and locally (Yuhanif, Anisah & Latifah, 2011). Therefore, if the doctor 
does not disclose full information as required by the Malaysian Guidelines for Good Clinical 
Practice, then invariably it mean that the doctor-investigators have neglected or ignored their 
professional responsibilities as set out in the Code of Professional Conduct 1987. As a result, 
doctor-investigators can be disciplined for his or her abusing privileges and professional skills 
that are nomenclaturely referred to in the Code of Professional Conduct 1987 as infamous 
conduct. 
3. 3 Proposed Framework Model in Aspects of Information Disclosure 
The Code of Professional Conduct 1987 was never amended till to date. With the exponential 
development in medical sciences and the progressive pace therein occasioned in clinical trials 
the once blissed code of 1987 is no longer able to address the fouling ethical problems and 
standards from the current clinical trials activities which have a major impact on the patient as 
subject. In addition, there is only one provision which discusses aspects of the information 
disclosure. Clause 1.5.1 of the Code has underlined that, “In any research on human beings, 
each potential subject must be adequately informed of the aims, methods, anticipated benefits 
and potential hazards of the study and the discomfort it may entails. He or she should be 
informed that he or she is at liberty to abstain.”  Therefore, the authors have incorporated 
several new clauses as proposed to fine-tune some aspects of the information disclosure 
equivalent to the requirements of internationally recognized rights of patients as subjects as 
follows: - 
1.5  Duty to give full and reasonable explanation and information 
(1)  Before a clinical trial is carried out or conducted, the doctor investigator shall give the 
subject and any person giving consent on behalf of the subject, a full and reasonable 
explanation of the following: 
(a) that the clinical trial involves research; 
(b) the purpose of the clinical trial; 
(c) the treatments to be administered in the clinical trial and the probability for random 
assignment of each treatment; 
(d) the procedures to be followed in the clinical trial, including all invasive procedures; 
(e) the responsibilities of the subject; 
(f) the aspects of the clinical trial which are experimental; 
(g) the reasonably foreseeable risks or inconveniences to the subject; 
(h) the reasonably expected benefits, including whether there is any intended clinical 
benefit to the subject; 
                                                          
4 Although it did not carry the force of law, the Nuremberg Code was the first international document which 
advocated voluntary participation and informed consent. 
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(i) any alternative procedures or treatments available to the subject, and their potential 
benefits and risks; 
(j) any compensation and treatment available to the subject in the event of injury arising 
from participation in the clinical trial; 
(k) any pro-rated payment to the subject for participating in the clinical trial;  
(l) any anticipated expenses to the subject from participating in the clinical trial; 
(m) that the subject’s participation in the clinical trial is voluntary and that he may refuse to 
participate in or may withdraw from the clinical trial at any time without penalty or loss 
of benefits which the subject would otherwise be entitled; 
(n) the persons who will be granted access to the subject’s medical records and the extent of 
such access, including the possibility that the licensing authority may inspect the 
records; 
(o) the extent to which records identifying the subject will be kept confidential; 
(p) that the subject or his legal representative will be informed in a timely manner of any 
information becoming available which may be relevant to the subject’s willingness to 
continue participating in the clinical trial; 
(q) the persons to contact for further information relating to the clinical trial and the rights 
of subjects and in the event of injury arising from participation in the clinical trial; 
(r) any foreseeable circumstances under or reasons for which the subject’s participation 
may be terminated; 
(s) the expected duration of the subject’s participation in the clinical trial; 
(t) the approximate number of subjects involved in the clinical trial; and 
(u) any other information which the licensing authority may require to be given. 
(2)  If any information becomes available which may be relevant to a subject’s willingness to 
continue participating in a clinical trial, the doctor-investigator shall, at the earliest feasible 
opportunity, give to the subject or his legal representative a full and reasonable explanation of 
that information. 
1.6  Compelling person to participate in research 
(1)  Any doctor-investigator who — 
(a) by means of coercion or intimidation, compels another person against that person’s will 
to participate or continue to participate as a research subject in any clinical trial;  
(b) by means of coercion or intimidation, compels another person (A) against A’s will to 
give A’s consent or to refrain from withdrawing A’s consent for the participation of 
another person (B) as a research subject in any clinical trial; 
(c) by means of deception or misrepresentation, causes another person to participate or 
continue to participate as a research subject in any clinical trial; or 
(d) by means of deception or misrepresentation, causes another person (A) to give A’s 
consent or to refrain from withdrawing A’s consent for the participation of another 
person (B) as a research subject in any clinical trial. 
1.1 Person qualified to procure informed consent 
 
Doctor-investigator or any person assisting him in clinical trial shall not conduct the 
informed consent process with the exception of a non participating third party doctor 
who himself is not a doctor-investigator in that particular clinical trial. 
1.2 Conflict of interest in clinical trial 
 
Doctor-investigator or any person assisting him in clinical trial or any subject in a 
clinical trial shall not, directly or indirectly, have any conflict of interest in the trial. 
1.9    Monitoring procedure in informed consent process 
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Any doctor-investigator shall — 
(a) video tape the process of informed consent during clinical trial 
(b) submit a copy of the informed consent process to the ethics committee 
(c) submit a copy to the archieves section for a duration of seven (7) years for the 
purpose of auditing 
 
2.0      Penalty 
 Any doctor-investigator who fails to comply with the above provisions shall be 
considered as being guilty of infamous conduct in any professional respect according to 
section 29 (2) (b) Medical Act 1971. As such the Malaysian Medical Council may impose 
disciplinary punishment under section 30 Medical Act 1971. 
 
The above clauses are proposed to be included in the Code of Professional Conduct 1987 to 
ensure that doctor-investigators disclose information to the patient,so that the safety aspect of 
the patient as subject is guaranteed. The word "shall" is used to ensure that doctor-investigators 
are not practicing doctor paternalism in disclosing information during the process of informed 
consent. The authors opined that the doctor-investigators are mandatorily required to disclose 
information to the patient-subject as the directive word ”shall” had been transcribed in the 
proposed amendment to the 1987 code. In other words, the doctor-investigators mandatorily 
need to disclose information in accordance with the provisions of the Code of Professional 
Conduct. Even with the existence of the Code of Professional Conduct, patients can still take 
legal action against the doctor-investigators either through Tort or Royal Prerogative through 
Judicial Review under Rule 53 of the Rules of Court 2012. Both methods of legislative action is 
also known as Grivience Procedures. 
3. 4 Others Proposals 
(i) Awareness programs to doctor-investigators on the responsibility to disclose information 
to patients 
 
Informed consent has been recognized globally in clinical trials aimed at protecting the patient-
subject from being exploited by doctor-investigators. Therefore, it is the responsibility of the 
doctor-investigators to disclose full information so that a rational decision can be made by the 
patient to accept or decline the invitation to participate in the trials. Hence, the information to 
be communicated is proposed within the framework of the proposed model in terms of 
information disclosure above (provision 1.5 - 2.0 Code of Professional Conduct 1987). Despite 
the views of experts who surmised that this is difficult to be realized because of the different 
level of comprehension amongst some patients or there is a knowledge gap between patient-
doctors, thus hindering the patient to understand the information conveyed which with all 
decorum are not subscribed by the authors. In other words, the authors believe that doctor-
investigators cannot assume that the patient-subject is not able to know or understand the 
information presented to him/her. As professionals, they should endevour their level best and 
try to find a way to ensure that all information presented can be understood by the patient-
subject. For example, in a 1998 study, schizophrenic patients participating in randomized 
clinical trials of different antipsychotic medications were first given informed consent forms to 
read and sign. The study found that the patients were able to understand the material in the 
forms. Even one week later, the patients were able to answer most of the questions asked about 
“the study’s procedures and goals, patients’ available choices as participants, their doctors’ 
responsibilities to the study, and potential ill effects of antipsychotic drugs that were to be given 
in the trial” (Brannigan & Boss, 2001). The underlying rationale is simple and straight forward 
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that doctor-investigator cannot deny the rights of patient-subjects to get information which is 
their right. 
 
(ii)  To remove the Perception "A doctor knows best" among doctor-investigators. 
The off-cited rationale of the differential in the level of education and knowledge of the patient-
subject and the doctor-investigator could not be a basis and excuse to deny patients of their 
rights to make their own decisions even to the extend that it is contrary to the views or 
intentions of doctor-investigators. How well intentioned be of a doctor-investigator to assist the 
patients, but the penultimate decision to so decide on the available and comprehensively 
advised by the said doctor shall, in all propensity lie with the patient himself/herself without 
more. In other words, good intentions cannot legalize patient rights to decide to participate in 
clinical trials or not. Furthermore, the trials itself mean that something is in trial and not 
definite only then subsequent to that will if be known to be of benefit or otherwise. Therefore, 
the doctor-investigators need to have a mind shift and change his/her perception that they know 
best than the patients. 
 
(iii) Awareness programs to patients/public to seize the opportunity to gain a better 
treatment by participating in clinical trials 
Basically, clinical trials in Malaysia is still new compared to countries that are more advanced in 
clinical research such as Singapore and the United States. The advantages or benefits that can be 
gained from participation is relatively unknown to patients in particular and the Malaysian 
society in general. Therefore, due to this disinformation, clinical trial is seen as something 
negative. People in the past thought that the purpose of doctor-investigators conducting clinical 
trials is to 'dabble' and be harmful to patients who are akine to guinea pigs in scientific land. 
Unlike in the West, where everyone wants to participate in clinical trials hoping to get better 
treatment. For example, patients with pediatric cancer who still has no curative treatment, but 
when told that there are new drugs that will be tested eventhough not confirmed as to its 
effectiveness as only 60% survival rate did not prevent patients from taking part to have the 
opportunity to get something better (personal communication with an expert from UKM  
Medical Centre, October 27, 2015). Therefore, campaign or awareness programs to 
patients/communities such as Clinical Trials Day or Lets Participate in Clinical Trials for the 
chance to get a better treatment should be carried out. 
 
In addition to awareness programs, the use of electronic print and electronic media can also be 
used to provide education opportunities to obtain a better treatment by participating in clinical 
trials. Hence, a way forward to educate the public and make them better exposed to the 
wholesome benefit of clinical trials are varied and amongst others is through issuing flyers, 
booklets, phamplets and other parapernalias which are catchy and could attract attentions. The 
task is not have to be shouldred alone by Ministry of Health, but all other institutions that 
conduct research and clinical trials have to bring home the good and benefit of the trials and to 
dispel apathy amongst the public. A testimony worth sharing by the authors themselves that a 
lackadaisical sense of urgency in so doing was evident when there was absence of 
literatures/books/phamplets and the like on the display at the shelves or counters in hospitals 
or institutions that conduct the clinical trials for public readings either advertisement or 
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In conclusion, the enforcement of the obligation to disclose information about the trials by 
doctor-investigators to patients is significant to protect patients in terms of recognizing their 
rights. This is because without the law enforcement, doctor-investigators would not follow the 
Malaysian Guidelines for Good Clinical Practice to disclose information to the patients. With the 
enforcement of the law in terms of the disclosure of information through the Code of 
Professional Practice 1987, the autonomy of the patient and doctor paternalism can be balanced. 
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